We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Drug Combination Selectively Prevents Cancer Cell Growth

By LabMedica International staff writers
Posted on 12 Jan 2017
Print article
Image: A ball-and-stick model of the metformin molecule (Photo courtesy of Wikimedia Commons).
Image: A ball-and-stick model of the metformin molecule (Photo courtesy of Wikimedia Commons).
The antihypertension drug syrosingopine has been found to drastically reduce the concentration of the diabetes medication metformin required to destroy cancer cells in culture and in a mouse liver cancer model.

Metformin is the most widely used antidiabetic drug in the world, and there is increasing evidence of a potential efficacy of this agent as an anticancer drug. First, epidemiological studies showed a decrease in cancer incidence in metformin-treated patients. Second, metformin decreased insulin resistance and indirectly reduced insulin level, a beneficial effect because insulin promotes cancer cell growth. Third, several reports outlined a direct inhibitory effect of metformin on cancer cell growth and an anti-tumor action. Finally, metformin activated the AMP activated protein kinase (AMPK) pathway, a major sensor of the energetic status of the cell, which has been proposed as a promising therapeutic target in cancer.

Since the concentration of metformin needed to inhibit the growth of cancer cells induces unwanted side effects, investigators at the University of Basel screened over a thousand drugs for any that could enhance the anticancer action of the diabetes drug.

The investigators reported in the December 23, 2016, online edition of the journal Science Advances that the antihypertensive syrosingopine, a derivative of reserpine, was synthetically lethal with metformin and that both compounds interacted synergistically to kill a broad variety of cancer cell types while demonstrating no activity against normal cells. In mice with malignant liver cancer, enlargement of the liver was reduced after combination therapy. Furthermore, treated animals had fewer tumor nodules, and in some animals the tumors disappeared completely.

In addition to promoting the anticancer effect of metformin, synthetic lethality with syrosingopine was also observed with every inhibitor of the mitochondrial electron transport chain tested. The synthetic lethal interaction evoked by syrosingopine and mitochondrial inhibitors occurred at concentrations substantially below the toxic threshold for either compound alone.

"We have been able to show that the two known drugs lead to more profound effects on cancer cell proliferation than each drug alone," said first author Dr. Don Benjamin, a post-doctoral researcher at the University of Basel. "The data from this study support the development of combination approaches for the treatment of cancer patients. For example, in samples from leukemia patients, we demonstrated that almost all tumor cells were killed by this cocktail and at doses that are actually not toxic to normal cells, and the effect was exclusively confined to cancer cells, as the blood cells from healthy donors were insensitive to the treatment."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.